Related Experiment Video
Updated: Aug 5, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Selective CB2 Agonist JWH-133 Suppresses Viability and Migration-Related Responses in Prostate Cancer Cells
Seda Sabah Özcan1, Rehime Yapar1, İsmail Değerli1
1Department of Medical Biology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 4500, Türkiye.
Pharmaceuticals (Basel, Switzerland)
|July 28, 2026
Summary
The cannabinoid receptor type 2 (CB2) agonist JWH-133 impacts prostate cancer cells by reducing viability and colony formation. Its effects on cell cycle and apoptosis genes vary by cell line.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cannabinoid receptor type 2 (CB2) agonists show promise for targeting tumor-related processes.
- Prostate cancer remains a significant health concern, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the effects of the selective CB2 agonist JWH-133 on prostate cancer cell lines.
- To analyze JWH-133's impact on cell viability, proliferation, migration, and gene expression.
Main Methods:
- MTT assay for cell viability.
- Colony formation and wound-healing assays for proliferation and migration.
- Quantitative real-time PCR for cell-cycle and apoptosis gene expression.
Main Results:
- JWH-133 reduced prostate cancer cell viability, colony formation, and migration in a dose- and time-dependent manner.
- The compound differentially affected cell lines (LNCaP, DU-145, PC3).
- JWH-133 modulated cell-cycle and apoptosis gene expression in DU-145 and PC3 cells.
Conclusions:
- JWH-133 demonstrates potential as a modulator of prostate cancer cell behavior.
- Effects are cell-line specific, indicating varied molecular pathway involvement.
- Further research is needed to elucidate the precise molecular mechanisms.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...